Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech to fund Alzheimer’s antibodies development
Immune believes the agreement will provide it with a solid financial basis beyond the next three years to develop other programs at full speed. Beta-amyloid constitutes an important
Immune believes the agreement will provide it with a solid financial basis beyond the next three years to develop other programs at full speed. Beta-amyloid constitutes an important
While the Roskamp Institute’s primary focus is on Alzheimer’s disease, Roskamp researchers have a significant interest in multiple sclerosis (MS). This is due to findings that suggest there
The FDA is holding a two-day advisory committee session to examine the safety of stents, a medical device inserted into damaged arteries which are designed to prop open
The finding offers clinicians a way to identify patients who are likely to develop diarrhea as a side effect from taking these drugs, the researchers said. The discovery
Although the risk is already acknowledged among children and teenagers, the FDA has been studying the risk in adults. The analysis, published ahead of an advisory panel meeting
At the end of the study, Lexapro patients demonstrated greater improvement than Cymbalta patients as measured by a standard depression rating system known as MADRS (Montgomery and Aasberg
NB S101 contains strontium malonate as its active ingredient. The primary endpoint of the study is the change in patients' bone resorption. Osteologix plans to enroll postmenopausal women
In six-week trials, bifeprunox improved symptoms in patients with acute exacerbations of schizophrenia but showed a smaller mean effect than did active references compared to placebo. Bifeprunox also
The trial is designed to evaluate PD-02's potential to slow the progression of Parkinson's disease. PD-02 is Avicena's proprietary therapeutic that has demonstrated the potential to improve neurological
ArQule also updated progress in its other clinical programs. These include three phase II trials with the first-generation E2F-1 compound, ARQ 501, as monotherapy in leiomyosarcoma and head